文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

功能性精准医学指导复发或难治性儿童癌症治疗的可行性

Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers.
PubMed 文献 · Nat Med · 2024-04-11

这项前瞻性观察性研究纳入25例复发或难治性实体瘤及血液肿瘤儿童患者,21例完成药物敏感性检测(DST),20例完成基因组分析,中位周转时间分别为10天内和27天。19例(76%)获得治疗推荐,14例接受干预,6例接受后续FPM指导治疗;其中5例(83%)无进展生存期较前次治疗改善超过1.3倍,且与8例非指导治疗患者相比无进展生存期和客观缓解率显著提高。

要点

  • 25例复发或难治性儿童癌症患者入组,19例(76%)获得FPM治疗推荐。
  • DST和基因组分析中位周转时间分别为10天内和27天。
  • 6例接受FPM指导治疗者中5例(83%)无进展生存期改善超过1.3倍。

核心结论

  • 这项原理验证研究显示FPM可能对复发或难治性儿童及青少年癌症患者的临床诊疗产生积极影响,并需在大型前瞻性研究中进一步验证。

研究设计与样本

  • 前瞻性观察性研究,纳入25例复发或难治性实体瘤和血液肿瘤儿童患者,其中21例接受DST、20例完成基因组分析。

主要发现

  • DST和基因组分析的中位周转时间分别为10天内和27天。
  • 19例(76%)获得治疗推荐,其中14例接受治疗干预,6例接受后续FPM指导治疗。
  • 6例接受FPM指导治疗的患者中5例(83%)无进展生存期较前次治疗改善超过1.3倍。
  • FPM指导治疗患者与8例非指导治疗患者相比,无进展生存期和客观缓解率显著提高。

关键数值与推荐

  • 主要目标为在临床可操作时间窗(<4周)内向FPM肿瘤委员会(FPMTB)实时返回基于FPM的治疗推荐的可行性。

局限性

  • 原文指出该研究为原理验证研究,需在大型前瞻性研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with rare, relapsed or refractory cancers often face limited treatment options, and few predictive biomarkers are available that can enable personalized treatment recommendations. The implementation of functional precision medicine (FPM), which combines genomic profiling with drug sensitivity testing (DST) of patient-derived tumor cells, has potential to identify treatment options when standard-of-care is exhausted. The goal of this prospective observational study was to generate FPM data for pediatric patients with relapsed or refractory cancer. The primary objective was to determine the feasibility of returning FPM-based treatment recommendations in real time to the FPM tumor board (FPMTB) within a clinically actionable timeframe (<4 weeks). The secondary objective was to assess clinical outcomes from patients enrolled in the study. Twenty-five patients with relapsed or refractory solid and hematological cancers were enrolled; 21 patients underwent DST and 20 also completed genomic profiling. Median turnaround times for DST and genomics were within 10 days and 27 days, respectively. Treatment recommendations were made for 19 patients (76%), of whom 14 received therapeutic interventions. Six patients received subsequent FPM-guided treatments. Among these patients, five (83%) experienced a greater than 1.3-fold improvement in progression-free survival associated with their FPM-guided therapy relative to their previous therapy, and demonstrated a significant increase in progression-free survival and objective response rate compared to those of eight non-guided patients. The findings from our proof-of-principle study illustrate the potential for FPM to positively impact clinical care for pediatric and adolescent patients with relapsed or refractory cancers and warrant further validation in large prospective studies. ClinicalTrials.gov registration: NCT03860376 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Acanda De La Rocha AM, Berlow NE, Fader M, et al. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat Med. 2024. PMID: 38605166. doi:10.1038/s41591-024-02848-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。